Shares of PYC Therapeutics (ASX:PYC) were flat in early trading on Tuesday after it reported late Monday a fiscal first-half loss of AU$0.0391 per share, compared with AU$0.0548 a year earlier.
Revenue for the six months ended Dec. 31, 2025, was AU$11 million, compared with AU$12.7 million a year earlier.